FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034250610> ?p ?o ?g. }

• W2034250610 endingPage "S768" @default.
• W2034250610 startingPage "S768" @default.
• W2034250610 abstract "Introduction The problem of coupling neuronal activity to a given hemodynamic change is one whose solution is paramount for proper interpretation of either task-related or pharmacologicallyinduced brain mapping experiments. A large number of vasoactive molecules are present in the brain, and many are also neurotransmitters. Such molecules include, among others, dopamine, adenosine and acetylcholine. Dopaminergic ligands such as cocaine and amphetamine produce strong hemodynamic responses in dopamine rich regions of the brain. In order to better understand the factors that may couple a change in dopamine concentration to a hemodynamic change we studied the effects of dopaminergic and adenosinergic antagonists upon MRI signal changes induced by amphetamine (AMPH). Method s Drugs 1) Amphetamine enhances the release of dopamine; 2) SCH-23390 is a selective D1 antagonist; 3) Eticlopride is a selective D2 anatagonist. It can disrupt autoregulation of dopamine release via the D2 autoreceptor; 4) DMPX is an A2 antagonist with some selectivity for A2a over A2b. (1). MRI Sprague-Dawley rats were used in this study. All studies were perfomred on a 4.7T GE Omega CSI. A conventional GE sequence was used to acquire images (TR/TE 600ms/20ms) as described earlier (2). A superparamagnetic contrast agent, mion, was used to sensitize the phMRI signal to rCBV changes. Baseline images were collected before and after mion injection, then AMPH was injected (2 or 3mg/kg) and 20 min afterwards, the selective antagonist ligand (SCH23390 (0.50.75mg/kg ip; n=5), or DMPX (5mg/kg iv; n=6) was injected. rCBV maps were created by converting signal intensity changes to ∆R2* changes. The degree of the blockade (Blockindex) was determined by the percent changes in the integration of ∆rCBV (Σ∆rCBV) over the pure-AMPH period (Σ∆rCBVAMPH) and 20 min after the post-treatment of the antagonist ligand (Σ∆rCBVantagonist): Blockindex = (Σ∆rCBVAMPH Σ∆rCBVpost)/ Σ∆rCBVAMPH Eticlopride (0.2mg/kg; n=6) was injected before AMPH (3mg/kg), these data were collected using BOLD imaging as described in (2). Results and Discussion We first investigated the effects of dopaminergic antagonists upon the regional hemodynamic changes induced by AMPH. We found that SCH-23390 caused a partial decrease in the AMPH-induced signal changes immediately upon injection of SCH-2390 as shown in Fig. 1A. Our prior data indicated that SCH-23390 completely blocked the effects of the cocaine analog β-CFT (3). We also investigated the effects of D2 antagonism upon AMPH-induced signal changes. In contrast to the D1 effects, D2 antagonism potentiated the effects of AMPH, causing a prolonged timecourse for the signal changes with no change in the overall magnitude (Fig. 1B). These effects are consistent with antagonism of pre-synaptic D2 autoreceptor induced regulation of dopamine release. Both pharmacological and behavioral studies indicate that dopamine D2 receptors and adenosine A2 receptors act in an antagonistic fashion (4). A1 and the A2b receptors are widely distributed over the brain while the A2a receptors are primarily, and most densely, localized in the basal ganglia (4). Administration of the A2 antagonist DMPX results in antagonism of the hemodynamic changes induced by AMPH that is quite strong in the striatum, and weaker in the frontal cortex. This is shown by maps of both the CBV changes induced by AMPH alone (Fig. 2A) and then by the decrease in CBV induced by DMPX (displayed as a Blockindex map in Fig. 2B). Plots of CBV changes in striatum and frontal cortex after DMPX administration are shown in Fig. 3. Administration of DMPX alone resulted in very small global decreases in CBV that could not explain the large effects on AMPH-induced changes (not shown). The results are summarized in Table I. Conclusions These results are consistent with prior data suggesting that dopamine is a coupling agent between neuronal activity and a CBV change (2). The D1 antagonism further suggests that the dopamine effects may be modulated by D1 receptors on the vasculature. Second, they point out that dopaminergic control through A2 receptors has an important modulatory influence upon hemodynamic effects. These experiments point the way towards methods to develop a more complete understanding of the neuronal-vascular coupling problem that is common to both fMRI and phMRI." @default.
• W2034250610 created "2016-06-24" @default.
• W2034250610 creator A5005925439 @default.
• W2034250610 creator A5013605309 @default.
• W2034250610 creator A5027397904 @default.
• W2034250610 creator A5056597400 @default.
• W2034250610 creator A5065184944 @default.
• W2034250610 date "2000-05-01" @default.
• W2034250610 modified "2023-10-16" @default.
• W2034250610 title "Neurogenic control of pharmacologically induced hemodynamic changes" @default.
• W2034250610 doi "https://doi.org/10.1016/s1053-8119(00)91697-5" @default.
• W2034250610 hasPublicationYear "2000" @default.
• W2034250610 type Work @default.
• W2034250610 sameAs 2034250610 @default.
• W2034250610 citedByCount "0" @default.
• W2034250610 crossrefType "journal-article" @default.
• W2034250610 hasAuthorship W2034250610A5005925439 @default.
• W2034250610 hasAuthorship W2034250610A5013605309 @default.
• W2034250610 hasAuthorship W2034250610A5027397904 @default.
• W2034250610 hasAuthorship W2034250610A5056597400 @default.
• W2034250610 hasAuthorship W2034250610A5065184944 @default.
• W2034250610 hasConcept C154945302 @default.
• W2034250610 hasConcept C15744967 @default.
• W2034250610 hasConcept C164705383 @default.
• W2034250610 hasConcept C169760540 @default.
• W2034250610 hasConcept C178853913 @default.
• W2034250610 hasConcept C2775924081 @default.
• W2034250610 hasConcept C41008148 @default.
• W2034250610 hasConcept C71924100 @default.
• W2034250610 hasConcept C98274493 @default.
• W2034250610 hasConceptScore W2034250610C154945302 @default.
• W2034250610 hasConceptScore W2034250610C15744967 @default.
• W2034250610 hasConceptScore W2034250610C164705383 @default.
• W2034250610 hasConceptScore W2034250610C169760540 @default.
• W2034250610 hasConceptScore W2034250610C178853913 @default.
• W2034250610 hasConceptScore W2034250610C2775924081 @default.
• W2034250610 hasConceptScore W2034250610C41008148 @default.
• W2034250610 hasConceptScore W2034250610C71924100 @default.
• W2034250610 hasConceptScore W2034250610C98274493 @default.
• W2034250610 hasIssue "5" @default.
• W2034250610 hasLocation W20342506101 @default.
• W2034250610 hasOpenAccess W2034250610 @default.
• W2034250610 hasPrimaryLocation W20342506101 @default.
• W2034250610 hasRelatedWork W2074204064 @default.
• W2034250610 hasRelatedWork W2128757228 @default.
• W2034250610 hasRelatedWork W2222804138 @default.
• W2034250610 hasRelatedWork W2336394759 @default.
• W2034250610 hasRelatedWork W2386180798 @default.
• W2034250610 hasRelatedWork W2398392351 @default.
• W2034250610 hasRelatedWork W2443613542 @default.
• W2034250610 hasRelatedWork W2467171063 @default.
• W2034250610 hasRelatedWork W2471113440 @default.
• W2034250610 hasRelatedWork W2473422508 @default.
• W2034250610 hasVolume "11" @default.
• W2034250610 isParatext "false" @default.
• W2034250610 isRetracted "false" @default.
• W2034250610 magId "2034250610" @default.
• W2034250610 workType "article" @default.